… study provides Class IV evidence that for patients with ALS, spinal cord transplantation of
human stem cells … This study lacks the precision to exclude important benefit or safety issues. …

… The goals of this phase 1 trial were to assess the safety … neural stem cells in the spinal cord,
and to examine the use of immunosuppression in ALS subjects, using a risk escalation study …

… of more homogenous future phase I, II, and III … : Our study reached the primary endpoint,
and our results underscore that micro-transplantation of cells into the human anterior spinal cord …

… We transplanted GMP-grade, fetal human neural stem cells … horns of the spinal cord to test
for the safety of both cells and … study on six patients with ALS shows that transplantation of …

… of human-spinal-cord-derived neural stem cell (NSI-566) transplantation for the treatment
of chronic spinal cord injury (SCI). In this clinical … for ALS: Analysis of phase 1 and 2 trials. …

… This study shows that one administration of engineered neural progenitors can provide …
cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation. …

… in the prospect of transplanting stem cells into the nervous system for the … spinal cord‐derived
stem cells (HSSCs) into the lumbar … This is a phase I study, focusing on the issues of safety …

… spinal cord-derived neural stem cell (HSSC) transplantation … amyotrophic lateral sclerosis
(ALS); however, previous trials … survival of our study cohort – Ph1/2 ambulatory limb-onset ALS …

… spinal cord neural progenitor cells and the pipeline starting from preclinical studies to the
designs of phase I and IIa clinical trials … Although the phase I study was not designed to …

… Each injection deposited 100 000 neural stem cells derived from a fetal spinal cord. Twelve
patients … This study uses a methodology that has been carefully developed and validated as …